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Many sensations of pain are evoked by mechanical stimuli, and in
inflammatory conditions, sensitivity to such stimuli is commonly
increased. Here we used cultured sensory neurons as a model of
the peripheral terminal to investigate the effects of inflammatory
signaling pathways on mechanosensitive ion channels. Activation
of two of these pathways enhanced transduction in a major
population of nociceptors. The proinflammatory neurotrophin
nerve growth factor caused an up-regulation of mechanically
activated currents via a transcriptional mechanism. Activators of
PKC, given in vitro and in vivo, also caused an increase in mechan-
ically activated membrane current and behavioral sensitization to
mechanical stimulation, respectively. The effect of activating PKC
was inhibited by tetanus toxin, suggesting that insertion of new
channels into the cell membrane is involved in sensitization. These
results reveal previously undescribed mechanisms by which PKC
and nerve growth factor synergistically enhance the response of
nociceptors to mechanical stimuli, suggesting possible targets for
pain treatment.
allodynia u dorsal root ganglia u hyperalgesia u mechanosensation u pain
Inflammatory pain conditions are commonly associated withincreased sensitivity to mechanical stimuli. In such conditions,
normally innocuous mechanical stimuli can become painful
(allodynia), and noxious stimuli can evoke enhanced pain re-
sponses (hyperalgesia). The mechanisms that underlie these
phenomena include both central and peripheral sensitization to
sensory input. Centrally, enhanced responsiveness to nociceptor
activity and activation of nociceptive pathways by low-threshold
mechanoreceptors both can contribute to hypersensitivity (1).
Additionally, the excitability of primary nociceptors can be
increased by changes in the function of voltage-gated ion chan-
nels or by augmentation of the mechanotransduction process (2).
Although the prevalence of peripheral mechanical sensitization
has been questioned in cutaneous C fiber nociceptors (3, 4), there
are extensive data showing peripheral sensitization to mechanical
stimuli of nociceptors innervating a variety of deep tissues, includ-
ing the meninges (5), joints (6), viscera (7), and injured axons
terminating in neuromas (8, 9). Therefore, increased mechanosen-
sitivity could play a major role in the pathophysiology of headache,
arthritis, visceral pain, and neuropathic pain.
The development of hyperalgesia to heat stimuli depends on
TRPV1 (10, 11), a heat-gated ion channel modulated in multiple
ways by inflammatory mediators, such as nerve growth factor
(NGF) and bradykinin, at the levels of transcription, translation,
and posttranslation (12–14). However, with no unequivocal data
regarding the identity of the mechanotransducing ion channels in
mammalian sensory neurons, understanding of the molecular
mechanisms of mechanical sensitization lags behind that of thermal
sensation. Signaling molecules normally present at the peripheral
nerve ending in vivo are present on the cell bodies of cultured
sensory neurons (15, 16), allowing such cells to be used as a model
for the study of transduction processes that normally occur in the
sensory terminal. Taking this approach, we have previously char-
acterized mechanotransduction in cultured dorsal root ganglion
(DRG) neurons, finding that mechanical stimulation evoked cat-
ionic membrane currents and that distinct neuronal subpopulations
had distinct mechanosensitive properties (17). In the present study,
we investigated whether signaling pathways involved in inflamma-
tion modulate the mechanotransducing properties of DRG neu-
rons. It is shown that exposure of a major subclass of nociceptive
neurons to NGF and activators of PKC (but not activators of PKA)
significantly enhanced mechanosensitivity through distinct mecha-
nisms. In the presumptive TrkA-expressing population of nocicep-
tors, NGF increased the transcription of new mechanosensitive ion
channels or a factor that modulates them. Conversely, activation of
PKC dramatically increased current amplitude by recruiting chan-
nel proteins to the cell surface.
Results
Inflammatory mediators are known to increase nociceptor excit-
ability via activation of PKC- and PKA-dependent signaling path-
ways (2, 18). To test whether activation of these pathways aug-
mented responses to mechanical stimulation in cultured neurons,
cells were incubated overnight in 200 nM forskolin (Fsk, a mem-
brane permeant activator of adenylyl cyclase) or 10 nM phorbol
12-myristate 13-acetate (PMA) (a phorbol ester that activates
PKC). Then, using the perforated-patch technique, voltage-clamp
recordings of mechanically activated (MA) currents were made.
Strikingly, PMA induced an increase of .250% in the peak
response to mechanical stimulation (3.42 6 0.39 nA, n 5 7, P 5
0.001), whereas currents in Fsk-treated neurons (1.35 6 0.35 nA,
n 5 7) were unchanged from control values (1.28 6 0.32 nA, n 5
7) (Fig. 1 a and b). In contrast, voltage-activated sodium currents
recorded after overnight PMA exposure (7.35 6 3.10 nA, n 5 30)
were not significantly above control values (6.28 6 2.08 nA, n 5 26,
P 5 0.14). Testing a range of PMA concentrations (0.1–10 nM)
showed that its effects were dose-dependent, with a 250% aug-
mentation of MA currents seen at 1 nM (Fig. 1c). It was also found
that exposure of neurons to 10 nM PMA for 1 h increased the peak
MA current amplitude to levels equivalent to currents in neurons
receiving overnight treatment, although it was notable that at lower
stimulus intensities, overnight treatment had a greater effect (Fig.
1d). The efficacy of a 1-h treatment in enhancing mechanosensi-
tivity strongly suggested that PKC acted by inducing a posttrans-
lational modification of the transduction apparatus (see below), and
all subsequent applications of PMA were for 1 h (unless otherwise
stated). To confirm that PMA acted through activation of PKC,
neurons were preincubated with the PKC-specific inhibitor bisin-
dolylmaleimide I, and in this condition, PMA (30 nM for 20 min)
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failed to significantly increase MA current over control values
(0.99 6 0.18 nA, n 5 15, vs. 0.80 6 0.15 nA; n 5 13; P 5 0.15) (Fig.
1e), whereas PMA alone approximately doubled its amplitude
(1.56 6 0.37 nA; n 5 11; P 5 0.055 vs. control). In separate
experiments (Fig. 1f), neurons treated with the inactive enantiomer
of PMA, a-PMA, had small MA currents (0.29 6 0.11 nA, n 5 10)
5-fold lower than in sister cultures treated with PMA (1.59 6 0.43
nA, n 5 8). To assess whether the large MA currents seen after
PMA treatment had similar characteristics to those seen in baseline
conditions, we tested whether the efficacy of ruthenium red and
amiloride in blocking the underlying ion channels remained con-
stant (Fig. 1 g and h). Ruthenium red (5 mM) blocked MA currents
by approximately half (residual current: 46 6 2%, n 5 4, vs. 49 6
1%, n 5 5) in each case, whereas amiloride failed to block MA
currents in either control or PMA-treated neurons (96 6 2%, n 5
4 vs. 100 6 2%, n 5 5), thus suggesting that the same ion channels
are being activated in both states.
Previously (17, 19) and during the above experiments, we cul-
tured neurons in NGF; to determine whether NGF regulates
mechanosensitivity, we cultured adult rat neurons with and without
it and then recorded MA currents either in control conditions or
after PMA treatment (Fig. 2a). NGF had a striking effect; its
omission precluded the expression of large-amplitude MA currents,
even after application of PMA. In neurons with neither NGF nor
PMA, themeanmaximal current sizewas ,100 pA (0.08 6 0.03 nA,
n 5 18), and although addition of PMA induced a trend toward
current augmentation, it was not significant (0.34 6 0.08 nA, n 5
25, P 5 0.2). However, in PMA-treated groups, the presence of
NGF in culture increased current amplitude by .9-fold (1.32 6 0.22
nA, n 5 36, vs. 0.14 6 0.04 nA, n 5 25, P , 0.001). To determine
that neurons in each groupwere of the same subpopulation and that
NGF had not affected cell viability, we compared their cell size
distribution. As is evident in Fig. 2b, we recorded from neurons that
had equally distributed somatic diameters, ranging from '28 to 50
mm. However, those neurons that responded strongly to NGF had
diameters of ,40 mm (Fig. 2c), consistent with a nociceptive
phenotype and the expression pattern of the high-affinity NGF
receptor TrkA in DRG (20).
Next we investigated whether distinct nociceptor populations
were differentially sensitive to the effects of PMA and neurotro-
phins. To distinguish between populations, we labeled neurons with
Isolectin B4 (IB4). IB4 binds nonpeptidergic, c-Ret-expressing
neurons, that give rise to nociceptiveC fibers, but not small-medium
sensory neurons that give rise to TrkA-positive, Ad-fiber, and
peptidergic, C fiber nociceptors (20). Consistent with our previous
findings in neonatal neurons (17), in adult rat neurons cultured with
NGF, we found that IB41 neurons not exposed to PMA were
essentially insensitive to mechanical stimulation (0.02 6 0.00 nA,
n 5 11; Fig. 2d). PKC activation led to the appearance of MA
currents in some of these cells, although on average, responses were
not significantly increased (0.14 6 0.04 nA, n 5 29, P 5 0.10; Fig.
2d). Conversely, in IB42 neurons, PMA considerably increased
peak MA current amplitude from 0.15 6 0.04 nA (n 5 15) to 0.91 6
0.10 nA (n 5 84, P , 0.001; Fig. 2d). Most IB41 neurons have small
cell bodies (20); however, in this study, we selected size-matched
IB41 and IB42 neurons in the range of 28–52 mm (Fig. 2e). MA
current amplitude in PMA-treated cells was independent of cell-
size amongst IB41 neurons; however, those IB42 neurons that
responded most to mechanical stimulation after PMA treatment
had cell bodies of ,40 mm in diameter (Fig. 2f). Together these
data suggest that in a subset of IB42 neurons, PKC activation
substantially enhances mechanosensitivity and that this effect de-
pends on prior exposure to NGF.
Given that TrkA receptors are localized to IB42 nociceptors,
whereas IB41 neurons express the glial cell line-derived factor
(GDNF) receptors c-Ret and GFRa1 (21), we tested whether
Fig. 1. Activationof PKC increasesMAcurrent amplitude inneonatal sensory
neurons. (a) Examples of voltage-clamp recordings of neurons responding to
incrementing mechanical stimuli (2–14 mm) in control conditions (Left) and
incubated overnight with PMA (10 nM; Right). (Calibration: vertical, 0.8 nA;
horizontal, 100 ms.) (b) Average peak response to 14 mmmechanical stimulus
in control conditions, overnight Fsk, and overnight PMA. (c) Overnight PMA
increased MA current amplitude in a concentration dependent manner (one-
way ANOVA, P , 0.001): control (1.076 0.18 nA; n 5 13), 0.1 nM (1.916 0.55
nA; n 5 5), 1 nM (2.726 0.82 nA; n 5 5; P 5 0.04 vs. control), and 10 nM (3.646
0.33 pA; n 5 11; P , 0.01 vs. control). (d) MA currents evoked by increasing
membranedisplacements (from4 to14mm) in control neurons (E, 14-mmstep:
0.626 0.30 nA; n 5 6), neurons treated overnight with 10 nM PMA (‚, 2.286
0.68 nA; n 5 6; P 5 0.05 vs. control), and neurons treated for 1 h with 10 nM
PMA (ƒ, 1.676 0.22 nA; n 5 6; P 5 0.02 vs. control). (e) Average peak response
to 14-mmmechanical stimulation in control neurons and in those treatedwith
either PMAalone or PMAplus bisindolylmaleimide I (1mM, applied for 15min
before PMA). ( f) Neurons treated with PMA had significantly larger MA
currents than neurons treated with a-PMA, the inactive enantiomer. (g) The
efficacy of ruthenium red in blockingMA currents was unchanged before and
after PMA treatment, whereas amiloride was ineffective in both conditions.
(h) Example traces showing current inhibition by ruthenium red. (Calibration:
top vertical, 0.2 nA; bottom vertical, 1 nA; horizontal, 100 ms.)
Fig. 2. MA currents are differentially regulated by PKC and trophic factors
in distinct neuronal subpopulations from adult rats. (a) Up-regulation of MA
currents by PMA depends on pretreatment with NGF. Graph shows average,
maximalMA currents in control conditions (and after 1-h incubation in 30 nM
PMA). (b) Cell diameter frequency distribution of all NGF-deprived (filled
columns; n 5 43) and NGF-treated (open columns; n 5 61) neurons used in a.
(c) Average peak MA current of PMA-treated cells seen in a, grouped accord-
ing to cell size (,35 mm, 35–40 mm, and .40 mm). Open columns, with NGF;
filled columns, no NGF. (d) Comparison of MA current amplitude, in control
conditions and after PMA treatment, in IB41 neurons and IB42 neurons. (e)
Cell diameter distribution of IB41 (filled columns; n 5 40) and IB42 (empty
columns; n 5 99) neurons used in d. ( f) Average peak MA currents in neurons
treated with PMA (from d) grouped according to cell diameter (,35 mm,
35–40 mm, and .40 mm) and IB4 labeling (filled columns, IB41, empty col-
umns, IB42).
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mechanosensitivity (after treatment with PMA) in the latter group
dependedonGDNF.However, as is shown inFig. 3a, whenneurons
were cultured in the presence of GDNF, IB41 and IB42 popula-
tions had currents that were of similar small amplitude (0.24 6 0.08
nA and 0.18 6 0.06 nA, respectively; n 5 18) and comparable to
those seen in IB41 neurons cultured in NGF (0.14 6 0.04 nA, n 5
29), whereas IB42 cells in this latter group had much larger MA
currents (0.95 6 0.15 nA, n 5 37). To further characterize the IB42
neurons that responded to PMA treatment, we determined their
sensitivity to capsaicin and also assessed the kinetics ofMAcurrents
expressed in control conditions and after PMA treatment. In a
sample of IB42 neurons with a similar size range to those used
above, where PMA enhanced MA currents to 337 6 43% of control
values, it was found that capsaicin activated an inward current
(.100 pA) in 88% (n 5 17) of control neurons and 79% (n 5 19)
of those treated with PMA, further indicating that these neurons
are polymodal nociceptors (data not shown). In this sample, we also
assessed the kinetics of MA currents to determine whether up-
regulated currents were kinetically similar to control currents. In
PMA-treated cells, total charge transfer increased proportionally to
peak current (307 6 57% of control) and current adaptation over
the stimulus duration was unchanged (105 6 5% of control; Fig.
3b). This result is further evidence that channels expressed normally
are those up-regulated by PKC activation. Finally, we observed the
behavior of these neurons in current-clamp conditions after treat-
ment with PMA andyor Fsk. Interestingly, activation of PKA by Fsk
acted synergistically with increasing MA currents through PKC
activation.Despite its lack of effect onMAcurrents, PKAactivation
alone increased the likelihood of neurons firing at least one action
potential from 10% (control, n 5 10) to 43% (Fsk, n 5 7).
Moreover, when Fsk and PMA were applied together, they in-
creased the incidence of repetitive firing from 0% observed in
control to 46% (n 5 13).
Having characterized the effects of PMA and NGF on the
mechanosensitivity of sensory neurons, we sought to determine the
mechanisms by which these compounds acted. First, we determined
how rapidly NGF modulates mechanosensitivity; IB4- neurons
were cultured either without NGF or with it for 1 or 8 h and then
treated with PMA before recording MA currents. This experiment
showed that the short-term (1 h) application of NGF was ineffective
in increasing mechanosensitivity (from 0.11 6 0.03 nA, n 5 30, to
0.17 6 0.09 nA, n 5 20), whereas after 8 h, MA currents were
substantially augmented (0.82 6 0.13 nA, n 5 54, P , 0.001 vs. no
NGF; Fig. 4a). This observation suggested that NGF acts by
increasing the production of new channel proteins whose activity
can be increased by activation of a PKC-dependent process. To
further test this hypothesis, we incubated neurons for 8 h in NGF,
either alone or in the presence of an inhibitor of gene transcription
(actinomycin) or an inhibitor of mRNA translation (cyclohexam-
ide). In neurons incubated with NGF alone, PMA treatment
induced a 350% increase in MA current amplitude (1.22 6 0.22 nA,
n 5 23, vs. 0.34 6 0.10 nA, n 5 9; P , 0.05); conversely, when
transcription or translation had been blocked, PMA failed to induce
a significant increase in current size (actinomycin: 0.57 6 0.16 nA,
n 5 12, P 5 0.27; cyclohexamide: 0.60 6 0.14 nA, n 5 21, P 5 0.25;
Fig. 4b). These data, coupled with the time course of NGF’s action,
lead us to conclude that NGF modulates mechanosensitivity by
inducing the synthesis of mechanosensitive ion channels (or an
auxiliary protein required for their function) via up-regulation of
Fig. 3. Regulation of adult nociceptor mechanosensitivity by neurotrophins
and PMA. (a) Average peak currents in IB4-labeled, PMA-treated neurons (30
nM for 1 h). Either NGF or GDNFwas applied overnight to culturemedium. (b)
Kinetics of MA currents are unchanged after PMA treatment. In a population
of IB42 neurons, peak current amplitudes and total charge transfer increased
at a similar rate after PMA, adaptation was unchanged. (c) Example traces
showing current adaptation and the parameters that were used for kinetic
analysis: total charge transfer was measured between points a and b; arrows
show residual current at the end of the stimulus used to calculate adaptation.
(Calibration: vertical, 0.3 nA; horizontal, 100 ms.) (d) Examples of current-
clamp recordings made from mechanically stimulated neurons (8-mm mem-
brane deflection): neuron cultured in control conditions (Left) and a neuron
incubated for 1 h with 30 nM PMA (Right). (Calibration: vertical, 20 mV;
horizontal, 100 ms.) (e) Probability of neurons firing either a single action
potential (open columns) of repetitively (filled columns) in response to me-
chanical stimulation in control conditions (10% and 0%, respectively; n 5 10)
or incubated for 1 h with 1 mM Fsk (43% and 14%; n 5 7), 30 nm PMA (44%
and 11%; n 5 9), or both (69% and 46%; n 5 13).
Fig. 4. Mode of action of NGF and time course of cellular and behavioral
effects of PMA. (a) MA currents in IB42, PMA-treated neurons (30 nM for 1 h).
Neurons were grownwithout NGF, or NGFwas applied before PMA for either
1 h or 8 h. Mean MA current amplitude recorded after 8 h NGF without PMA
was 0.246 0.06 nA (n 5 20, P 5 0.01 vs. NGF 8 h plus PMA). (b) Cycloheximide
(Chx) and actinomycine D (Act) inhibit the effect of NGF on MA currents in
IB42 neurons. Cells were treatedwith NGF for 8 h either alone orwith Chx (10
mgyml) or Act (5mgyml, eachwas added 1 hbeforeNGF), and then 30 nMPMA
was added for 1 h. (c) Effect of NGF on short-term (9–12 h) neonatal cultures.
Shown are current amplitudes evoked by incrementing mechanical stimuli in
IB42 neurons (no PMAadded). Currents recorded in neuronswithout NGF (E)
were significantly smaller than those in cells cultured in NGF (‚). (d) Average
peak MA currents in IB42 neurons incubated with PMA for 10 min or 1 h. (e)
Augmentation of MA currents by PKC activation is maintained after PMA is
removed. Shown are current amplitudes evoked by incrementing mechanical
stimuli in IB42 neurons. Currents recorded in control conditions (E) were
significantly smaller than those in cells treated with PMA for 1 h and then
washed for 4 h before recording (‚). ( f) PMA caused a dose-dependent
decrease in PWT after intraplantar injection. All doses of PMA induced a
decrease in PWT 1 h after injection. Three hours after injection, hyperalgesia
inducedby 160 and1,600 pmol per pawwasmaintained,whereas PWTs in rats
given the lowest dose returned to near control values (81.0 6 17.7% of
control, P 5 0.54) (n 5 4 in each group).
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gene transcription. It has been shown recently (22) that, because of
the coupling of TrkA receptor to intracellular pathways in DRG
neurons, acute regulation of TRPV1 by NGF undergoes matura-
tional changes and NGF is effective only in enhancing TRPV1
function in adult [more than postnatal day (P)12] neurons. In
contrast, we observed that if neonatal (P1) neurons were cultured
for 9–12 h with or without NGF, a significant enhancement of
mechanosensitivity was evident in the NGF-treated group (0.35 6
0.19 nA, n 5 8, vs. 1.29 6 0.32 nA, n 5 9, P , 0.05; Fig. 4c).
Next we examined the mechanism by which PKC activation
enhanced MA current amplitude. Using NGF-treated, IB42 neu-
rons only, the time course of PMA actions was studied further. It
was found that PMA exposure for either 10 or 60 min increased
current levels to comparable levels (1.03 6 0.20 nA, n 5 15, P 5 0.01
and 1.36 6 0.28 nA, n 5 11, P 5 0.005, respectively, vs. control:
0.12 6 0.06 nA, n 5 6; Fig. 4d), thus suggesting that PMA acted
rapidly to modify channel behavior. The same result was obtained
when PMA was directly applied to a patched neuron, for as little as
7 min, by using a perfusion pipe positioned next to the cell under
study (control: 0.41 6 0.07 nA, n 5 11; vs. PMA treated: 1.23 6 0.35
nA, n 5 8; data not shown). It was further determined that an
increase in MA current amplitude was maintained significantly
after the cessation of PKC stimulation. As is shown in Fig. 4e, after
neurons were exposed to PMA (30 nM) for 1 h, washed, and then
incubated in control conditions for 4 h before recording, MA
currents remained .300% of control values (0.77 6 0.23 nA, n 5
15, vs. 0.23 6 0.08 nA, n 5 13; P 5 0.043).
Peripheral PKC activation has been implicated in the induction
of mechanical hyperalgesia (23, 24) and the data presented in this
paper suggest a mechanism by which PKC activation can increase
the sensitivity of sensory neurons to mechanical stimulation. There-
fore, we determined whether intraplantar injections of PMA in-
duced mechanical hypersensitivity with a similar time course and
dose dependency as the effects we have observed in vitro. Using
automated von Frey testing, it was observed that 1 h after injection,
all doses of PMA (16, 160, and 1,600 pmol per paw in 50 ml) caused
a severe and dose-dependent reduction in the paw withdrawal
threshold (PWT) from a mechanical stimulus [PWT decreased by
64.5 6 7.7%, P , 0.01; 72.8 6 6.4%, P , 0.01; and 87.8 6 3.9% (P ,
0.001), respectively; Fig. 4f]. PWTs then were reassessed 3 h after
injection, and it was found that although there was a significant
recovery in those animals given 16 pmol PMA, mechanical hyper-
algesia was entirely sustained at the higher 2 doses (Fig. 4f). Hence,
the long-term maintenance of MA current enhancement in vitro
mirrors the sustained mechanical hypersensitivity observed in vivo.
Two aspects of the effect of PKC activation on MA current
amplitude suggested the possibility that the underlying mechanism
involved the insertion of new functional channels into the neuronal
membrane. First, the increase in current amplitude is maintained
for a substantial period after the removal of PMA. Second, the
apparent NGF-induced increase in ion channel synthesis was alone
insufficient to drastically augment MA current amplitude, thus
suggesting that newly synthesized channels are not functionally
present in the cell membrane. To test this hypothesis, we inhibited
vesicular exocytosis in sensory neurons by incubating them in
tetanus toxin (TeNT) before application of PMA; TeNT cleaves
vesicle-associated protein VAMP-2 to inhibit fusion of vesicles to
the cell membrane (25). This treatment inhibited the potentiation
of MA currents by PKC activation (Fig. 5a), implying that PMA
alone is sufficient to cause increased vesicular turnover. To test this
hypothesis further, we used FM1-43 to measure the amount of
membrane recycling. Neurons were treated with PMA for 20 min,
and the amount of FM1-43 labeling was compared to that of control
neurons. Unstimulated neurons showed a very limited time-
dependent incorporation of the dye indicative of a low level of
membrane recycling (Fig. 5 c and d). Consistent with PKC activa-
tion inducing exocytosis, when PMA and FM1-43 were added to
neurons together, there was a much higher degree of FM1-43
labeling than in control neurons; this increase was not significant at
5 min (447 6 64, n 5 12, vs. 306 6 55, n 5 11) but after 20 min,
labeling was almost 250% of control values (1,437 6 271, n 5 12,
vs. 614 6 151, n 5 11; P , 0.02) (Fig. 5 c–f). In separate
experiments, PMA was not found to evoke currents in patched
DRG neurons (n 5 11), negating the possibility that FM1-43 is
taken up via an ion channel mediated route. These data thus
support the notion that PKC activation by PMA increases mech-
anosensitivity in a subpopulation of DRG neurons by inducing de
novo insertion of mechanosensitive ion channels into the cell
membrane via a TeNT-sensitive pathway.
Discussion
This study sought to determinewhether signaling pathways involved
in inflammatory pain conditions directly modulate the mechano-
transduction apparatus of sensory neurons. It was found that in a
major subclass of nociceptors, two such pathways modulate mech-
anosensory ion channels. Activation of the PKC signaling cascade
increased the mechanosensitivity of DRG neurons by inducing
insertion of new transduction channels into the cell membrane,
whereas NGF acted at the transcriptional level to increase the
availability of these channels or a factor that allows PKC-dependent
membrane insertion of the channel (Fig. 5b). NGF levels increase
during inflammation (26), and NGF previously has been found to
increase transcript levels of TRPV1 (12) and proinflammatory B2
bradykinin receptors (27). PKC-induced insertion of channels was
Fig. 5. PKC activation up-regulates MA currents by a mechanism involving
insertion of new channels in the membrane. (a) TeNT inhibits sensitization of
MA currents by PMA. Shown are average responses to increasing mechanical
stimulation (up to 14 mm) in neonatal neurons. PMA alone up-regulates MA
currents (ƒ; peak: 1.38 6 0.16 nA, n 5 24; P , 0.005 vs. control), but after an
8-h incubation in TeNT (20 nM), PMA had no effect on current amplitude ({;
mean at 14 mm: 0.79 6 0.18 nA, n 5 24; P , 0.05 vs. PMA-treated cells). Peak
control current was 0.64 6 0.16 nA (E, n 5 16). (b) Schematic representation
of the proposed mechanisms underlying peripheral sensitization to mechan-
ical stimulation. NGF, acting via trkA receptors, increases transcription of MA
channels, which are packaged into vesicles. Activation of PKC by proinflam-
matory signals induces fusion of the vesicles and insertion of new mechano-
sensitive channels into the cell membrane. (c) Epifluorescence images taken 5
min (Left) and 20 min (Right) after FM1-43, a marker of vesicle recycling, was
applied to neurons bathed in control extracellular solution (horizontal bar: 40
mm.) (d) Quantitative analysis of the mean fluorescence (arbitrary units) in 11
neurons whose images were taken as described in c (F, 5 min; E, 20 min),
measured along a 40-mm segment (indicated by yellow line in c). Segments
were drawn such that each cell’s profile could be superimposed for compar-
ison. (e) As in c, but FM1-43 was coapplied with 30 nM PMA. ( f) Analysis as in
d, but neurons (n 5 12) were treated with PMA as in e.
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via a VAMP-2 dependent vesicular mechanism, as demonstrated by
tetanus toxin sensitivity, whereas the maintenance of enhanced
mechanosensitivity hours after the removal of PMA suggests newly
inserted channels remain stable in the membrane. Consistent with
this interpretation, we found that PKC activation increased the rate
of vesicular trafficking as demonstrated by a PMA-induced increase
in FM1-43 labeling of neurons. Both regulatory mechanisms that
we observed were developmentally maintained, with qualitatively
similar effects of PMA and NGF observed in neonatal and adult
neurons. PKA activation had no effect on the amplitude of MA
currents, but when applied with PMA, had a synergistic effect in
increasing action potential firing rates, which could be due to
complementary effects on voltage-gated ion channels by PKA,
(e.g., NaV1.8, see ref. 28).
Control of the rate of insertion of ion channels into the cell
membrane by vesicular trafficking recently has been the subject of
a number of studies. Of particular interest are results concerning
members of the TRP channel family, given their general function
in sensory systems (29) and the possibility that MA currents are
mediated by members of this family (19). For example, TRPC3 is
inserted into the cell membrane in a VAMP-2-dependent manner
(30), and the surface expression of TRPC5 is regulated in this way
by growth factors (31). Moreover, TRPV1, which functions in
thermal sensation and hyperalgesia (10, 11), has been shown to
associate with two vesicular proteins, whereas in oocytes, activation
of PKC increased channel density at the cell surface (14). Hence,
ion channel trafficking has an important role in regulating neuronal
function in general, and specifically it may play a major role in
altering the sensitivity of DRG nerve terminals to physical stimuli.
At this stage, it remains unclear which PKC isoform is responsible
for mediating membrane insertion of mechanosensitive ion chan-
nels, and it will be of interest to determine whether the same one
also regulates the trafficking of TRPV1. Interestingly, PKC« null
mutants have major deficits in mechanical hyperalgesia induced by
epinephrine, whereas a specific inhibitor of PKC« inhibited cara-
geenin-induced mechanical hypersensitivity (32). PKC« is abun-
dant in DRG neurons and translocates to the cell membrane after
activation by bradykinin (13).
The effect of NGF was specific to IB42 neurons of ,40 mm in
diameter, the same population of neurons that were most affected
by PKC activation. These data suggest that NGF acts through TrkA
receptors located on peptidergic nociceptors and Ad-fiber nocicep-
tors. A nociceptive phenotype of cultured rat neurons with diam-
eters up to 40 mm is strongly supported by the observation that a
substantial number of IB42 neurons in this size range respond to
capsaicin, display wide action potentials, and express neuropeptides
(33). Furthermore, in a sample of neurons in which we saw PMA
augmented mechanosensitivity, the vast majority were capsaicin-
sensitive. The other major population of nociceptive neurons are
TrkA-negative, IB41 neurons, which express C-ret in adulthood
(20, 21). However, even when neurons were cultured in the pres-
ence of GDNF, this population displayed very small MA currents
despite the application of PMA. These data raise the possibility that
different classes of nociceptors detect mechanical stimuli by using
distinct mechanisms. IB41 neurons may indirectly detect noxious
mechanical stimuli via the release of a chemical intermediary
released from mechanically damaged cells (34). Dai et al. (35) have
produced evidence that activation of P2X3 receptors, which are
almost exclusively expressed by IB41 neurons, play a role in
mechanical hyperalgesia after completeFreund’s adjuvant, whereas
mechanically stimulated keratinocytes may also signal to DRG
neurons by releasing ATP (36).
In inflammatory pain states, increased levels of numerous me-
diators activate receptors on the sensory terminals of nociceptors to
regulate their excitability. Major pathways implicated in this process
include those dependent on PKA, PKC, and mitogen-activated
protein kinases; targets of these pathways include voltage-activated
channels and heat-activated channels (2, 18), and hyperalgesia in a
naturalistic setting will involve an interplay between many systems.
However, our behavioral data and that of others (24) show that
PKC activation is sufficient to induce mechanical hyperalgesia.
Furthermore, GPCRs known to be positively coupled to PKC via
PLC, such as bradykinin (37) and mGluR5 receptors (23, 38), have
been shown to play an important role in mechanical hypersensi-
tivity. Likewise, NGF can induce mechanical hyperalgesia, and it
does sowith a latency of '3 h (39, 40); this delaymay imply a central
mechanism but our data, suggesting increased expression of a
protein required for augmented mechanotransduction, offers an
alternative explanation for this delay. It is noted that PMA can
activate cellular targets other than PKC, but it is widely held that
bisindolylmaleimide I, which binds PKC at a site distinct from the
PMA-binding domain, is a selective inhibitor of PKC (41). Also,
some phorbol esters are reported to induce ion channel activity, but
in our experience, PMA very rarely induces cationic currents in
sensory neurons (13, 42). Therefore, PMA effects on MA currents
or FM1-43 uptake cannot be accounted for by such a mechanism.
At present, the strongest evidence of a robust peripheral sensi-
tization to mechanical stimuli comes from studies of the nociceptive
innervation of joints (6), the viscera (7), the dura (5), and from
nerve endings in neuromas (8, 9). In each case, chemical stimulation
leads to a decrease in mechanical threshold and increased suprath-
reshold firing. Most studies have used a combination of inflamma-
tory mediators, meaning the intracellular pathways underlying
sensitization are unresolved, although Neugebauer et al. (43)
showed bradykinin alone sensitized articular afferents of the knee
joint. We recorded from unlabeled neurons from DRG of all spinal
levels so were not aware of the peripheral targets of the neurons
used. However, given the specificity of PMA- and NGF-induced
sensitization to IB42 neurons, it is of interest to note that noci-
ceptive afferents of deep tissues that display pronounced mechan-
ical sensitization are predominately peptidergic neurons. IB41
neurons are absent from the knee joint (44) and account for only
20% of colonic nociceptors (45), whereas an extensive peptidergic
innervation of the dura has been characterized (46). This distribu-
tion contrasts with cutaneous nociceptors, most of which bind IB4
(45, 47). The mechanisms underlying peripheral mechanical sen-
sitization are unclear; augmentation of currents carried by voltage-
gated sodium channels are likely to contribute (2), and we propose
that recruitment of previously uncharacterized mechanosensitive
ion channels to the membrane surface will also substantially
increase sensitivity.
In conclusion, the molecular understanding of mechanotrans-
duction is still very poor, and very little is known about modulation
of this sensory modality in different pain states. Using a functional
assay of mechanosensitivity that utilizes cultured neurons as a
model of peripheral terminals, we identified two mechanisms
potentially involved in nociceptor plasticity after inflammation.
These mechanisms may play important roles in visceral pain,
arthritis, migraine pain, and neuropathic pain.
Experimental Procedures
Cell Culture. Cells were cultured from neonatal (P1 and P2) and
adult (P24–P35) Sprague–Dawley rats (17, 19). Briefly, animals
were decapitated, and 20–25 DRG were dissected from them.
Ganglia were digested by using collagenase type XI and protease
type IX and then mechanically triturated before cells were resus-
pended in culture medium and plated on poly(L-lysine) and lami-
nin. Medium was DMEM with fetal bovine serum, glutamine, and
penicillin-streptomycin. NGF (100 ngyml) (Promega) or 10 ngyml
GDNF (Peprotech) was added as required. Recordings were made
16–30 h after plating. Experimental neurons were compared with
control neurons from that day’s cultures to compensate for inter-
culture variability.
Electrophysiology. Neurons with isolated cell bodies were selected
for recording. Electrophysiological recordings were made at a
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holding potential of 270 mV (voltage-clamp configuration) or at
resting potential (current-clamp configuration) by using an Axo-
patch 200B amplifier (Axon Instruments). Data were acquired at 20
kHz by using PCLAMP 8 software (Axon Instruments). Experiments
were performed in the perforated-patch configuration with a
pipette solution containing 90 mM potassium acetate, 50 mM KCl,
1 mM MgCl2, and 10 mM Hepes, pH 7.35 (pH was corrected by
using KOH); 200 mgyml amphotericin B was added immediately
before recording. The extracellular solution contained 140 mM
NaCl, 4 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 4 mM D-glucose, and
10 mM Hepes, pH 7.4. Drugs were prepared on the day of the
experiment from stocks kept at 220°C at a concentration at least
1,000-fold the working concentration.
Neurons were mechanically stimulated (17, 19) by using a
heat-polished glass pipette (tip diameter '5 mm), controlled by a
piezo-electric crystal drive (Burleigh Instruments, Fishers, NY).
The probe moved at 0.5 mmymsec, and the stimulus was applied for
200 msec. To assess the mechanosensitivity of a neuron, a series of
mechanical steps in 2-mm increments up to 14 mm were applied at
15-sec intervals. Current adaptation was measured as the percent-
age decrease in current amplitude from the peak to the end of the
stimulus plateau.
Cell Labeling. To label neurons with IB4, cells were incubated in 3
mgyml IB4-Alexa 488 (Molecular Probes) for 10 min and then
washed twice in extra cell solution before cell selection. The
fluorescent dye FM1-43 (2 mM; Molecular Probes) was added to
the dish, with or without PMA, immediately before placing the cells
on the stage of a Zeiss Axiovert 200 microscope equipped for
epifluorescence. A neuron was randomly selected from the plate in
bright-field mode and then fluorescent images of it were taken after
5 and 20 min [Apogee Instruments (Roseville, CA) charge-coupled
device camera]. Analysis was performed by using MICROCCD soft-
ware, a 40-mm line was drawn with the cell’s edge at 10 mm, then
for statistics, we compared a single point from midway across each
cell after subtraction of background values.
Behavioral Testing. Mechanical withdrawal thresholds were mea-
sured by using an automated von Frey hair applicator, calibrated to
apply a pressure ramp of 50 g over 20 sec. At each time point, three
stimuli were applied to the animals’ left hind paws, and the mean
of these three values was taken. Animals (P28 on day 1) were
habituated to the testing room on day 1 and to testing on days 2 and
3. On day 4, a baseline reading was taken 1 h before injection, and
then the animals were assessed 1 and 3 h after injection. Injections
were given under light anesthesia (2–4% halothane). Drugs were
given in a 50-ml volume of standard external solution; controls
received a concentration of DMSO (1.62%) equivalent to those
animals receiving 1.6 nmol of PMA.
Data Analysis. Unless otherwise stated, the mean peak amplitude of
MA currents in response to a 14-mm mechanical stimulus was used
to assess the mechanosensitivity of each group of neurons. Groups
were then compared by using the Student t test unless otherwise
stated. Data were analyzed by using SIGMAPLOT 8.0 and SIGMASTAT
4.0 software (Systat Software, Point Richmond, CA).
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